Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Flavonoids of Diels et Gilg Against Acute Hepatic Injury by Blocking PI3K/AKT Signaling Pathway.
Mediators Inflamm
January 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
This study aims to investigate the mechanism of Diels et Gilg flavonoids (THF) on acute hepatic injury (AHI). First, high-performance liquid chromatography (HPLC) fingerprints were established to obtain the main chemical components of THF. According to the network pharmacology databases, collect active targets of AHI and potential targets.
View Article and Find Full Text PDFConcurrent leiomyosarcoma causing small bowel obstruction in a patient with non-Hodgkin lymphoma.
BMJ Case Rep
January 2025
Colorectal Surgery, Monash Health, Clayton, Victoria, Australia.
Small bowel obstruction (SBO) is a leading cause of general surgery inpatient admissions. SBO is most commonly associated with postoperative adhesions; however, neoplastic SBO is an important differential. Here, we present a case of neoplastic SBO secondary to leiomyosarcoma in a patient with known mature B cell lymphoma.
View Article and Find Full Text PDFRare Case of Mantle Cell Lymphoma With Multiple Rectal Lesions.
United European Gastroenterol J
January 2025
Department of Gastroenterology and Digestive Endoscopy, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
BCL6 Alleviates Hepatic Ischemia/Reperfusion Injury Via Recruiting SIRT1 to Repress the NF-κB/NLRP3 Pathway.
Transplantation
January 2025
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Background: Hepatic ischemia/reperfusion (I/R) injury (HIRI) is an intrinsic phenomenon observed in the process of various liver surgeries. Unfortunately, there are currently few options available to prevent HIRI. Accordingly, we aim to explore the role and key downstream effects of B-cell lymphoma 6 (BCL6) in hepatic I/R (HIR).
View Article and Find Full Text PDFMetabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study.
Diabetes Obes Metab
January 2025
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Diseases in the Population, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Background: Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories of steatotic liver disease (SLD) recently proposed by nomenclature consensus group and cancer risk.
Methods: A total of 283 238 participants from the UK Biobank were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!